Researchers show dual-target CD19/CD22 #CARTTherapy plus ASCT achieves durable survival in #TP53-mutated r/r aggressive #BNHL, offering curative potential with consistent long-term safety and paving the way for next-gen #immunotherapies.

#OpenAccess in #STTT: doi.org/10.1038/s413...